Personalizing CAR T: Making the Right Call for Each Patient

Opinion
Video

Panelists discuss how patient-specific characteristics in diffuse large B-cell lymphoma significantly impact chimeric antigen receptor T-cell (CAR T) therapy outcomes, suggesting that standardized treatment algorithms may need refinement. Factors like tumor biology, immune status, and genetic profiles could help optimize therapeutic selection and sequencing.

Recent Videos
5 experts in this video
Related Content